Sana Biotechnology (NASDAQ:SANA) Shares Down 3.4%

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) traded down 3.4% during trading on Wednesday . The stock traded as low as $5.16 and last traded at $5.17. 467,107 shares traded hands during trading, a decline of 82% from the average session volume of 2,635,602 shares. The stock had previously closed at $5.35.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Sana Biotechnology in a research report on Thursday, May 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $12.75.

Sana Biotechnology Stock Performance

The business has a fifty day moving average of $7.57 and a 200-day moving average of $7.43. The company has a market capitalization of $1.16 billion, a P/E ratio of -3.41 and a beta of 1.46.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC lifted its position in Sana Biotechnology by 46.1% in the 4th quarter. Corient Private Wealth LLC now owns 413,360 shares of the company’s stock worth $1,687,000 after buying an additional 130,500 shares during the last quarter. Rafferty Asset Management LLC grew its stake in Sana Biotechnology by 34.7% in the fourth quarter. Rafferty Asset Management LLC now owns 437,614 shares of the company’s stock worth $1,785,000 after purchasing an additional 112,732 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Sana Biotechnology in the third quarter worth $2,091,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock worth $93,000 after acquiring an additional 17,753 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Sana Biotechnology by 1.2% in the third quarter. Vanguard Group Inc. now owns 9,167,585 shares of the company’s stock worth $35,479,000 after acquiring an additional 107,167 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.